Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Stavudine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 1.00 |
| ▸ | LMNA | P02545 | 1/20 | 1.00 |
| ▸ | ALB | P02768 | 1/20 | 1.00 |
| ▸ | POLB | P06746 | 1/20 | 1.00 |
| ▸ | ADRA1A | P35348 | 1/20 | 1.00 |
| ▸ | BLM | P54132 | 1/20 | 1.00 |
| ▸ | BCHE | P06276 | 7/20 | 0.52 |
| ▸ | TYMP | P19971 | 2/20 | 0.51 |
| ▸ | TK1 | P04183 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Stavudine SCHEMBL3234890 | 1.00 | ALDH1A1 (1.00) | ALDH1A1LMNAALBPOLBADRA1A | |
| Stavudine SCHEMBL8540086 | 1.00 | ALDH1A1 (1.00) | ALDH1A1LMNAALBPOLBADRA1A | |
| Stavudine SCHEMBL7150054 | 1.00 | ALDH1A1 (1.00) | ALDH1A1LMNAALBPOLBADRA1A | |
| Stavudine SCHEMBL38661 | 1.00 | ALDH1A1 (1.00) | ALDH1A1LMNAALBPOLBADRA1A | |
| Stavudine SCHEMBL3420352 | 1.00 | ALDH1A1 (1.00) | ALDH1A1LMNAALBPOLBADRA1A | |
| Stavudine SCHEMBL18474938 | 1.00 | ALDH1A1 (1.00) | ALDH1A1LMNAALBPOLBADRA1A | |
| Stavudine SCHEMBL6439535 | 1.00 | ALDH1A1 (1.00) | ALDH1A1LMNAALBPOLBADRA1A | |
| Stavudine SCHEMBL25259221 | 0.99 | ALDH1A1 (0.97) | ALDH1A1LMNAALBPOLBADRA1A | |
| Stavudine SCHEMBL29040943 | 0.99 | ALDH1A1 (0.97) | ALDH1A1LMNAALBPOLBADRA1A | |
| Stavudine SCHEMBL7249174 | 0.99 | ALDH1A1 (0.97) | ALDH1A1LMNAALBPOLBADRA1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 64 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023178127-A1 | METHODS OF TREATING MEDICAL CONDITIONS USING STAMPIDINE OR A RELATED COMPOUND | ROME THERAPEUTICS, INC. (US) | 2023-09-21 | — | — | WO | disclosed |
| WO-2023164472-A1 | METHODS OF TREATING MEDICAL CONDITIONS USING CENSAVUDINE OR A RELATED COMPOUND | ROME THERAPEUTICS, INC. (US) | 2023-08-31 | — | — | WO | disclosed |
| US-20230172961-A1 | THERAPEUTICS FOR COVID-19 | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2023-06-08 | — | — | US | disclosed |
| US-20230159574-A1 | BENZYLOXY PHOSPH(ON)ATE COMPOUNDS | CITIBANK, N.A., AS ADMINISTRATIVE AGENT | 2023-05-25 | — | — | US | disclosed |
| WO-2022256625-A1 | LINE-1 INHIBITORS AS COGNITIVE ENHANCERS | TRANSPOSON THERAPEUTICS, INC. (US) | 2022-12-08 | — | — | WO | disclosed |
| US-11040997-B2 | Process for preparing nucleoside prodrugs | NuCana plc (GB) | 2021-06-22 | — | — | US | disclosed |
| US-RE47589-E1 | Phosphoramidate compounds and methods of use | NuCana plc (GB) | 2019-09-03 | — | — | US | disclosed |
| EP-3235824-B1 | MIXTURE OF RP/SP GEMCITABINE-[PHENYL-(BENZYLOXY-L-ALANINYL)]-PHOSPHATE | UNIV COLLEGE CARDIFF CONSULTANTS LTD (GB) | 2019-03-27 | — | — | EP | disclosed |
| US-10005810-B2 | Process for preparing nucleoside prodrugs | UNIVERSITY COLLEGE CARDIFF CONSULTANTS LIMITED (GB) | 2018-06-26 | — | — | US | disclosed |
| US-10005810-B2 | Process for preparing nucleoside prodrugs | UNIVERSITY COLLEGE CARDIFF CONSULTANTS LIMITED (GB) | 2018-06-26 | — | — | US | disclosed |
| US-20070232529-A1 | mesalamine covalently attached to carrier peptide at C-terminus, interspersed and/or side chain; releasing into bloodstream; reducing dosage | NEW RIVER PHARMACEUTICALS INC. (US) | 2007-10-04 | — | — | US | disclosed |
| WO-2007060689-A2 | PROCESS FOR THE LARGE SCALE PRODUCTION OF STAVUDINE | MATRIX LABORATORIES LTD (IN) | 2007-05-31 | — | — | WO | disclosed |
| US-20070037977-A1 | Substituted-1, 3-oxathiolanes and substituted-1, 3-dioxolanes with antiviral properties | BELLEAU BERNARD | 2007-02-15 | — | — | US | disclosed |
| US-20070037975-A1 | Substituted-1,3-oxathiolanes and substituted-1, 3-dioxolanes with antiviral properties | BELLEAU BERNARD | 2007-02-15 | — | — | US | disclosed |
| US-20070037975-A1 | Substituted-1,3-oxathiolanes and substituted-1, 3-dioxolanes with antiviral properties | BELLEAU BERNARD | 2007-02-15 | — | — | US | disclosed |
| US-7172867-B2 | Methods of testing for allergic diseases, and therapeutic agents for treating same | GENOX RESEARCH, INC. (JP) | 2007-02-06 | — | — | US | disclosed |
| US-7173020-B2 | Phosphoramidates and methods therefor | PURDUE RESEARCH FOUNDATION (US) | 2007-02-06 | — | — | US | disclosed |
| US-7173020-B2 | Phosphoramidates and methods therefor | PURDUE RESEARCH FOUNDATION (US) | 2007-02-06 | — | — | US | disclosed |
| CN-1792364-A | Medicinal composition contg. stavudine and valproic acid or salts thereof | MINGXIN HIGH TECH DEV CO LTD B (CN) | 2006-06-28 | — | — | CN | disclosed |
| CN-1695632-A | Oral preparation of quick releasing stavudine, and producing method | MINGXIN HI TEH DEV CO LTD BEIJ (CN) | 2005-11-16 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230159574-A1 | BENZYLOXY PHOSPH(ON)ATE COMPOUNDS | PYGL, GOT2, ALPI | ALDH1A1 1307/4885LMNA 586/4885ALB 195/4885 |
| US-20070037977-A1 | Substituted-1, 3-oxathiolanes and substituted-1, 3-dioxolanes with antiviral properties | IFNAR1, MAVS, IFNG | ALDH1A1 848/4885LMNA 4245/4885ALB 1678/4885 |
| US-20230172961-A1 | THERAPEUTICS FOR COVID-19 | ACE, ACE2, PNP | ALDH1A1 1857/4885LMNA 3427/4885ALB 3707/4885 |
| US-20070037975-A1 | Substituted-1,3-oxathiolanes and substituted-1, 3-dioxolanes with antiviral properties | IFNAR1, MAVS, IFNG | ALDH1A1 911/4885LMNA 4227/4885ALB 1877/4885 |
| US-11040997-B2 | Process for preparing nucleoside prodrugs | PNP, TYMP, SLC29A1 | ALDH1A1 2544/4885LMNA 1767/4885ALB 1793/4885 |
| US-10005810-B2 | Process for preparing nucleoside prodrugs | PNP, TYMP, SLC29A1 | ALDH1A1 2729/4885LMNA 1709/4885ALB 2083/4885 |
| US-20070232529-A1 | mesalamine covalently attached to carrier peptide at C-terminus, interspersed and/or side chain; releasing into bloodstream; reducing dosage | VIP, BST2, FCGR3B | ALDH1A1 2406/4885LMNA 3203/4885ALB 45/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.